Corrigendum: Cinnamaldehyde suppressed EGF-induced EMT process and inhibits ovarian cancer progression through PI3K/AKT pathway

Y. Lynn Wang, Ying Li, Liang Wang, Buze Chen, Miaolin Zhu, Chunyi Ma, Chunyan Mu, Aibin Tao, Shibao Li, Lan Luo, Ping Ma, Shuai Ji, Ting LanFrontiers in Pharmacology 2024 · DOI · OpenAlex

Abstract

This article provides a formal corrigendum for the 2022 study investigating the anti-cancer properties of cinnamaldehyde (CA) in ovarian cancer. It specifically addresses a labeling error in the immunofluorescence imaging of Figure 3D while reaffirming that the original conclusions—that CA inhibits cancer progression via the PI3K/AKT pathway—remain scientifically sound and valid.

Addressing Ovarian Cancer Progression and EMT

The original research focused on the Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. EMT is a biological process where stationary epithelial cells transform into mobile mesenchymal cells, a key step in cancer metastasis. The study investigated whether cinnamaldehyde, a natural bioactive compound, could suppress this transition when triggered by Epidermal Growth Factor (EGF).

This corrigendum addresses a data integrity issue in the original publication where two panels in Figure 3D, representing different concentrations of CA treatment, were accidentally swapped. Such corrections are vital in peer-reviewed literature to ensure that visual evidence accurately supports the quantitative data.

Key Experimental Insights and Results

The researchers utilized A2780 and SKOV3 human ovarian cancer cell lines to track the effects of CA. By combining molecular biology and imaging techniques, they demonstrated that CA doesn't just stop cancer growth; it actively reverses the morphological changes induced by EGF.

Figure 3: Morphological and molecular effects of Cinnamaldehyde (CA) on EGF-induced EMT. (A) Phase-contrast microscopy of cell morphology. (B) Western blot analysis of EMT markers (E-cadherin, N-cadherin, vimentin, Snail). (C, D) Immunofluorescence staining for E-cadherin and N-cadherin.

Morphological Restoration and Protein Expression

As shown in Figure 3A, cells treated with EGF exhibit a spindle-shaped mesenchymal morphology. The addition of CA restores a more rounded, epithelial-like appearance. This is supported by Western blot data (Figure 3B), which shows a clear, dose-dependent increase in the epithelial marker E-cadherin and a decrease in mesenchymal markers like N-cadherin, vimentin, and Snail.

Visual Confirmation via Immunofluorescence

The corrected Figure 3D provides the accurate visual proof that CA treatment maintains N-cadherin at lower levels compared to the EGF-only control. This aligns with the quantitative findings from the Western blots. The use of DAPI (blue) for nuclear staining and specific antibodies (red) for target proteins allows for precise localization and intensity analysis.

The PI3K/AKT Signaling Pathway

By identifying the PI3K/AKT pathway as the primary target, the paper provides a specific molecular mechanism for how cinnamaldehyde exerts its effects. This pathway often acts as a "master switch" in cancer, regulating cell growth and survival. The study concludes that CA suppresses EMT by inhibiting this signaling cascade.

Limitations and Future Directions

While the in vitro results are promising, transitioning to in vivo animal models and clinical settings involves hurdles regarding the bioavailability and metabolism of cinnamaldehyde. Furthermore, while the PI3K/AKT pathway is a major player, future work might explore if CA affects other signaling cascades like TGF-β or Wnt/β-catenin to fully map its anti-cancer activity.

Summary updated

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.779608.].
BibTeX
@inproceedings{wang2024corrigendum,
  author = {Y. Lynn Wang and Ying Li and Liang Wang and Buze Chen and Miaolin Zhu and Chunyi Ma and Chunyan Mu and Aibin Tao and Shibao Li and Lan Luo and Ping Ma and Shuai Ji and Ting Lan},
  title = {{Corrigendum: Cinnamaldehyde suppressed EGF-induced EMT process and inhibits ovarian cancer progression through PI3K/AKT pathway}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1427330},
}
Figure